Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q06481
UPID:
APLP2_HUMAN
Alternative names:
APPH; Amyloid beta (A4) precursor-like protein 2; Amyloid protein homolog; Amyloid-like protein 2; CDEI box-binding protein; Sperm membrane protein YWK-II
Alternative UPACC:
Q06481; B3KXX9; H7BXI4; Q13861; Q14594; Q14662; Q71U10; Q7M4L3; Q9BT36
Background:
Amyloid beta precursor like protein 2 (APPH), also known as Amyloid beta (A4) precursor-like protein 2, plays a crucial role in hemostasis regulation. It interacts with G-protein signaling pathways and binds to DNA CDEI box. APPH inhibits several proteases including trypsin and plasmin, and modulates the degradation of GPC1 heparan sulfate side chains, showcasing its multifaceted biological functions.
Therapeutic significance:
Understanding the role of Amyloid beta precursor like protein 2 could open doors to potential therapeutic strategies.